They have enough money to get through the first part of phase I. If that yields solid results, the PPS should increase at least to the .30-.50 range. That will be enough for them to get more funding without hurting investor value. They will also get non toxic funding from a foreign licensing partner. And like I've said before, since this is an orphan drug, if the results are significant after phase II, they can push for an FDA approval and completely forego phase III. You also have to remember that positive results, if they are significant enough, make a small company such as Oncolix an attractive buyout target. Then it won't matter if we get volume, a buyout is the best thing that can happen.
IMO